Cimzia (certolizumab pegol)

About UCB

UCB S.A. is a multinational biopharmaceutical company founded in 1928, originally as Union Chimique Belge. The company has evolved from a diversified chemical company into a focused biopharmaceutical leader with approximately 8,500 employees worldwide. UCB concentrates on patient solutions in neurology and immunology, with a strong portfolio of approved medicines including Keppra for epilepsy, Cimzia for inflammatory diseases, and Vimpat for seizure disorders.

Therapeutic Areas